NASDAQ$CRMD
CorMedix Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
CorMedix reported a net loss for the fourth quarter of 2020, driven by increases in employee and market research costs. The company is focused on bringing DefenCath to hemodialysis patients.
CorMedix reported a net loss of $6.1 million for the fourth quarter of 2020, compared to a net loss of $5.3 million in the fourth quarter of 2019. The increase in net loss was primarily driven by increases in employee costs and market research costs. The company had $46.3 million in cash and short-term investments as of December 31, 2020.
- CorMedix recorded a net loss of $6.1 million, or $0.19 per share, in Q4 2020.
- Operating expenses for Q4 2020 were $6.1 million.
- The company believes it has sufficient resources to fund operations at least into the second half of 2022.
- CorMedix is focused on developing DefenCath for the prevention of bloodstream infections associated with central venous catheters.
Headline financials
Revenue & EPS history
CorMedix · Revenue · Quarterly
$55.7K
Forward guidance
CorMedix believes that, based on the Company’s cash resources at year end plus the $41.5 million in net proceeds from ATM issuances since the beginning of 2021, it has sufficient resources to fund operations at least into the second half of 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2020
-1.3%
Avg return
Earnings day
+1.1%
Avg return
5 days after
+12.4%
Avg return
30 days after
43%
20 / 47 earnings
Positive
+31.1%
Q3 2022
Best reaction
-31.8%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +5.7% | +4.4% | +16.7% | |
| Q4 2025 | -11.7% | -5.6% | -1.0% | |
| Q3 2025 | +2.1% | -10.8% | +2.7% | |
| Q1 2025 | +23.6% | +29.1% | +46.0% | |
| Q4 2024 | -31.8% | +13.8% | +98.2% | |
| Q3 2024 | -22.4% | -26.1% | -24.0% | |
| Q2 2024 | +27.0% | +36.5% | +83.9% | |
| Q1 2024 | -9.5% | -6.7% | -9.6% | |
| Q4 2023 | +10.8% | +8.2% | +81.5% | |
| Q3 2023 | +7.1% | +28.9% | +10.9% | |
| Q2 2023 | +6.1% | +7.3% | -8.5% | |
| Q1 2023 | -13.9% | -1.5% | +5.2% | |
| Q4 2022 | +13.1% | +16.4% | +35.0% | |
| Q3 2022 | +31.1% | +30.4% | +33.6% | |
| Q2 2022 | +22.8% | +26.6% | +10.1% | |
| Q1 2022 | +7.6% | +25.7% | -3.3% | |
| Q4 2021 | +3.4% | -1.4% | -37.6% | |
| Q3 2021 | +0.4% | -0.4% | -6.0% | |
| Q2 2021 | +7.1% | +4.2% | -21.7% | |
| Q1 2021 | -23.1% | -16.9% | +4.6% | |
| Q4 2020 | +15.0% | +16.1% | -1.4% | |
| Q3 2020 | -0.9% | +5.7% | +61.0% | |
| Q2 2020 | -0.5% | +5.6% | +10.0% | |
| Q1 2020 | -6.9% | -2.7% | +54.2% | |
| Q4 2019 | -22.5% | -31.3% | -3.8% | |
| Q3 2019 | +6.1% | +28.2% | +25.8% | |
| Q2 2019 | -2.8% | -0.6% | -3.6% | |
| Q1 2019 | -7.7% | -0.4% | +8.7% | |
| Q4 2018 | -1.6% | -14.6% | -0.5% | |
| Q3 2018 | -15.5% | +9.1% | +27.3% | |
| Q2 2018 | -21.7% | -25.0% | -1.7% | |
| Q1 2018 | -5.0% | -5.0% | +60.0% | |
| Q4 2017 | -19.4% | -32.3% | -32.3% | |
| Q3 2017 | +3.8% | -9.4% | +5.7% | |
| Q2 2017 | -5.4% | -2.7% | +16.2% | |
| Q1 2017 | -5.8% | -5.8% | -15.4% | |
| Q4 2016 | -12.2% | -22.0% | -40.5% | |
| Q3 2016 | -18.6% | -22.1% | -23.0% | |
| Q2 2016 | -7.1% | -8.4% | +18.8% | |
| Q1 2016 | -11.7% | — | — | |
| Q4 2015 | -5.2% | — | — | |
| Q3 2015 | -3.2% | — | — | |
| Q2 2015 | -3.8% | — | — | |
| Q1 2015 | — | — | — | |
| Q2 2014 | +5.9% | — | — | |
| Q2 2013 | +24.4% | — | — | |
| Q4 2013 | -1.2% | — | — | |
| Q2 2010 | +7.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro